Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: Result in a cohort of 203 resection specimens Aneil.

Slides:

Advertisements

Similar presentations

Identification of Novel Candidate Oncogenes and Tumor Suppressors in Malignant Pleural Mesothelioma Using Large-Scale Transcriptional Profiling Gavin J.

Advertisements

Lost in translation The Journal of Thoracic and Cardiovascular Surgery

Manuel J. Antunes, MD, PhD, DSc

“Lead from the front”: Participative leadership

Improving health care by embracing Systems Theory

Elizabeth H. Baldini, MD, MPH, William G. Richards, PhD, Ritu R

Philip A. Linden, MD, Richard J. Gilbert, MD, Beow Y

Same-day cancellation of cardiac surgery: A retrospective review at a large academic tertiary referral center Mark M. Smith, MD, William J. Mauermann,

Intrinsic cardiac stem cells are essential for regeneration

Centers for Disease Control “increased-risk” organ donor: Not so risky? Francis D. Pagani, MD, PhD The Journal of Thoracic and Cardiovascular Surgery

Abracadabra I, II…HeartMate 3?

Victor van Berkel, MD, PhD

William M. DeCampli, MD, PhD

What is the best approach for surgery of malignant pleural mesothelioma? It is to put our efforts into obtaining trustworthy evidence for practice Tom.

The lord of the rings Antonio Miceli, MD, PhD

Jared P. Beller, MD, Irving L. Kron, MD

Aldo R. Castañeda, MD, PhD: Recipient of the Lifetime Achievement Award and 74th president of The American Association for Thoracic Surgery Pedro J.

The variability of the mitral valve anatomy and terminology

Main stem bronchus surgery with pulmonary preservation

Support Your Specialty

Innovation and science: The future of valve design

The assessment of cost effectiveness and the effectiveness of cost assessment in cardiothoracic surgery Vinay Badhwar, MD The Journal of Thoracic and.

It's not “just a shunt” but sometimes it should be…

Military surgeons just want to have fun

Do we need a bibliometrician to know which way the wind is blowing?

A first start for lung transplantation?

Jules Lin, MD The Journal of Thoracic and Cardiovascular Surgery

Get it right the first time

Shawn S. Groth, MD, MS, R. Taylor Ripley, MD, Bryan M. Burt, MD

Characteristics of Malignant Pleural Mesothelioma in Women

Surgery for aortic and mitral valve disease in the United States: A trend of change in surgical practice between 1998 and 2005 Scott D. Barnett, PhD,

Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD

A randomized comparison of different ventilator strategies during thoracotomy for pulmonary resection Andrew D. Maslow, MD, Todd S. Stafford, MD, Kristopher.

Historical perspectives of The American Association for Thoracic Surgery: Robert M. Janes, MD ( ) Myunghyun Lee, MD, Vivek Rao, MD, PhD The.

Choice of second pericardial drainage tube for posterior placement

Resection of primary lung cancer with incidental pleural seeding: Seeds of change or reap what you sow? Jules Lin, MD The Journal of Thoracic and Cardiovascular.

Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD

Frank C. Spencer, MD, FACS, pioneering cardiothoracic surgeon

Frozen elephant trunk technique: Ready to get back to the future?

A fate worse than death Jennifer S. Lawton, MD

Attachment disorder in thoracoabdominal surgery

The Ross procedure: Time to reevaluate the guidelines

Manuel J. Antunes, MD, PhD, DSc

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

We are the company we keep: The importance of the tumor microenvironment Sai Yendamuri, MD, FACS The Journal of Thoracic and Cardiovascular Surgery

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

First nights, the adrenal axis, and steroids

The origins of open heart surgery at the University of Minnesota 1951 to 1956 Richard A. DeWall, MD The Journal of Thoracic and Cardiovascular Surgery

Positron emission tomography predicts survival in malignant pleural mesothelioma Raja M. Flores, MD, Timothy Akhurst, MD, Mithat Gonen, PhD, Maureen Zakowski,

Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural.

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

The continuing challenge of congenital heart disease in China

Bicuspid aortopathy: Seeing the forest for the trees

Ralph E. Delius, MD The Journal of Thoracic and Cardiovascular Surgery

Therapeutic R2 resection for pleural mesothelioma

The Journal of Thoracic and Cardiovascular Surgery

“The more things change…”: The challenges ahead

Why arch curvature affects arch resistance

Managing conflicts of interest

More than vital: Who bears the burden?

Preoperative PFTs: The answer is blowing in the wind

Of mice and men… The Journal of Thoracic and Cardiovascular Surgery

Who should decide margin length in pulmonary excision of lung cancer?

Is there a benefit to continuing with resection of all sites of disease when clinically occult pleural metastases from non–small cell carcinoma are found?

Did you like Terminator 3 better than Terminator 2

Journal changes and initiatives

Zone zero thoracic endovascular aortic repair is all about “location, location, location” Kevin L. Greason, MD The Journal of Thoracic and Cardiovascular.

Deciding how much to pay for effective care

Presentation transcript:

Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: Result in a cohort of 203 resection specimens Aneil A. Mujoomdar, MD, Tamara R. Tilleman, MD, PhD, William G. Richards, PhD, Raphael Bueno, MD, David J. Sugarbaker, MD The Journal of Thoracic and Cardiovascular Surgery Volume 140, Issue 2, Pages 352-355 (August 2010) DOI: 10.1016/j.jtcvs.2009.11.072 Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Drug resistance assay results among malignant pleural mesothelioma tumors. The Journal of Thoracic and Cardiovascular Surgery 2010 140, 352-355DOI: (10.1016/j.jtcvs.2009.11.072) Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Venn diagram: EDR and IDR for mesothlioma specimens. EDR, Extreme drug resistance; IDR, intermediate drug resistance. The Journal of Thoracic and Cardiovascular Surgery 2010 140, 352-355DOI: (10.1016/j.jtcvs.2009.11.072) Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Drug resistance in tumors with epithelial histology. Note: Y-axis is percentage. The Journal of Thoracic and Cardiovascular Surgery 2010 140, 352-355DOI: (10.1016/j.jtcvs.2009.11.072) Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

Figure 4 Drug resistance in tumors with nonepithelial histology. Note: Y-axis is percentage. The Journal of Thoracic and Cardiovascular Surgery 2010 140, 352-355DOI: (10.1016/j.jtcvs.2009.11.072) Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions